Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DepleTTR-CM phase 3 study of ALXN2220 in transthyretin amyloid cardiomyopathy
MOH_2024-02-04_013234Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing ALXN2220 with Placebo (2 arms). Primary endpoint: Composite of all-cause mortality and total cardiovascular clinical events. Started Jan 2024; status: active, not recruiting.
02
Drugs
cliramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on MOH_2024-02-04_013234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-04_013234.